Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma

Cancer Gene Therapy

Volumn 10, Issue 6, 2003, Pages 481-490

  Kellerman, Laurence Cordier ^a   Valeyrie, Laurence ^a   Fernandez, Nadine ^a   Opolon, Paule ^a   Sabourin, Jean Christophe ^a   Maubec, Eve ^a   Le Roy, Pierre ^b   Kane, Agnes ^c   Legrand, Agnes ^e   Abina, Mohamed Amine ^a,d   Descamps, Vincent ^a,e   Haddada, Hédi ^a,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b TRANSGENE S A   (France)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e BICHAT HOSPITAL   (France)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; Gene transfer; IFN ; Malignant mesothelioma; Recombinant adenovirus; TGF ; Tumor regression

Indexed keywords

ADENOVIRUS VECTOR; ASBESTOS; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GAMMA INTERFERON; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; GENE TRANSFER; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LYMPHOCYTIC INFILTRATION; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE SUBPOPULATION; TUMOR MODEL;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL SEPARATION; CYTOKINES; DNA, COMPLEMENTARY; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; MESOTHELIOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RNA; T-LYMPHOCYTES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0038616021     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700594     Document Type: Article

References (42)

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in North Western Cape Province. Br J Ind Med. 1960;17:260-271.
2. Craighead JE, Mossman BT. The pathogenesis of asbestos-associated diseases. N Eng J Med. 1982;306:1446-1455.
3. Sterman DH, Kaiser LR, Albeida SM. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am. 1998;12:553-568.
4. Ramael M, Van Meerbeeck JV, Van Marck EV. Mesothelioma, currents insights. Cancer J. 1994;7:174-180.
5. Kumar-Singh S, Weyler J, Martin MJH, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGFβ expression. J Pathol. 1999;189:72-78.
6. Ruffie PA. Pleural mesothelioma. Curr Opin Onc. 1991;3:328-334.
7. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in britain. Lancet. 1995;345:535-539.
8. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 1999;397:710-713.
9. Caminschi I, Venetsanakos E, Leong CC, et al. Cytokine gene therapy of mesothelioma. Immune and antitumoral effects of transfected interleukin-12. Am J Respir Cell Mol Biol. 1999;21:347-356.
10. Law MR, Hodson ME, Heard BE. Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. Thorax. 1982;37:810-815.
11. Graham FL, Van Der Eb EJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456-467.
12. Graham FL, Smiley J, Russel WC, Nairu R. Characteristics of a human cell line transformed by the DNA from human adenovirus 5. J Gen Virol. 1977;36:59-72.
13. Cordier L, Duffour MT, Sabourin JC, et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther. 1995;2:16-21.
14. Josien R, Douillard P, Guillot C, et al. A critical role for transforming growth factor-β in donor transfusion-induced allograft tolerance. J Clin Invest. 1998;102:1920-1926.
15. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by γ-interferon treatment. Cancer Res. 1994;54:4419-4423.
16. Fernandez N, Levraud JP, Haddada H, et al. High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local Il-12 therapy of cancer. J Immunol. 1999;162:609-617.
17. Baratin M, Ziol M, Romieu R, et al. Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther. 2001;8:193-202.
18. Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 785 pleural mesotheliomas. Chest. 1996;109:109-114.
19. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate. 1997;31:61-70.
20. Addison CL, Braciak T, Raltson R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
21. Wallach D, Fellous M, Revel M. Preferential effect of interferon-gamma on the synthesis of HLA antigens and their mRNAs in human cells. Nature. 1982;299:833-836.
22. Rosa F, Hatat D, Abadie A, et al. Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J. 1983;2:1585-1589.
23. Collins T, Korman AJ, Wake CT, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA. 1984;81:4917-4921.
24. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of peritoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res. 2001;61:6201-6212.
25. Gerwin BI, Lechner JF, Reddel RR, et al. Comparison of production of transforming growth factor-B and platelet-derived growth factor by normal human mesothelioma cells and mesothelioma cell lines. Cancer Res. 1987;47:6180-6184.
26. Fitzpatrick DR, Bielefeld-Ohmann H, Himbeck RP, et al. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors. 1994;11:29-44.
27. Torre-Amione G, Beauchamp RD, Koeppen H, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA. 1990;87:1486-1490.
28. Vodovotz Y, Bogdan C, Paik J, et al. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor B. J Exp Med. 1993;178:605-613.
29. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Patho- and immunobiology of malignant mesothelioma: characterisation of tumor infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother. 1994;39:347-359.
30. Serve H, Steinhauser G, Oberberg D, et al. Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines. Cancer Res. 1991;51:3862-3866.
31. Higashihara M, Sunaga S, Tange T, et al. Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer. 1992;70:2105-2108.
32. Schmitter D, Lauber B, Fagg B, et al. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992;51:296-301.
33. Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, et al. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon γ immunotherapy. Cancer Immunol Immunother. 1995;40:241-250.
34. Walker C, Everitt J, Ferriola PC, et al. Autocrine growth stimulation by transforming growth factor a in asbestostransformed rat mesothelioma cells. Cancer Res. 1995;55:530-536.
35. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF B-receptors whereas cultured normal mesothelioma cells express predominantly PDGF α-receptors. Oncogene. 1991;6:2005-2011.
36. Smythe WR, Kaiser LR, Hwang HC, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994;57:1395-401.
37. Boylan AM, Sanan DA, Sheppard D, et al. Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin alpha v beta 5. J Clin Invest. 1995;96:1987-2001.
38. Smythe WR, Hwang HC, Elshami AA, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg. 1995;222:78-86.
39. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Resp Cell Mol Biol. 1995;13:7-16.
40. Kucharczuck JC, Elshami AA, Zhang HB, et al. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thorac Surg. 1995;60:593-598.
41. Elshami AA, Kucharczu JC, Zhang HB, et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996;7:141-148.
42. Boulanger P. Cell receptors for human adenoviruses. J Soc Biol. 1999;193:77-84.